Once-Weekly Efpeglenatide Dose-Range Effects on Glycemic Control and Body Weight in Patients With Type 2 Diabetes on Metformin or Drug Naive, Referenced to Liraglutide.
Adult
Aged
Blood Glucose
/ drug effects
Body Weight
/ drug effects
Diabetes Mellitus, Type 2
/ blood
Double-Blind Method
Drug Administration Schedule
Drug Therapy, Combination
Female
Glucagon-Like Peptide-1 Receptor
/ agonists
Glycated Hemoglobin
/ drug effects
Humans
Hypoglycemic Agents
/ administration & dosage
Liraglutide
/ administration & dosage
Male
Metformin
/ administration & dosage
Middle Aged
Proline
/ administration & dosage
Treatment Outcome
Journal
Diabetes care
ISSN: 1935-5548
Titre abrégé: Diabetes Care
Pays: United States
ID NLM: 7805975
Informations de publication
Date de publication:
09 2019
09 2019
Historique:
received:
28
12
2018
accepted:
23
06
2019
pubmed:
20
7
2019
medline:
19
5
2020
entrez:
20
7
2019
Statut:
ppublish
Résumé
To explore the efficacy, safety, and tolerability of once-weekly efpeglenatide, a long-acting glucagon-like peptide 1 receptor agonist (GLP-1 RA), in early type 2 diabetes (T2D) (drug naive or on metformin monotherapy). EXCEED 203 was a 12-week, randomized, placebo-controlled, double-blind, parallel-group, dose-ranging study of efpeglenatide once weekly referenced to open-label liraglutide 1.8 mg (exploratory analysis). Participants, ∼90% on metformin monotherapy, were randomized to one of five efpeglenatide doses (0.3, 1, 2, 3, or 4 mg q.w.; From a baseline HbA Efpeglenatide once weekly led to significant reductions in HbA
Identifiants
pubmed: 31320446
pii: dc18-2648
doi: 10.2337/dc18-2648
doi:
Substances chimiques
Blood Glucose
0
Glucagon-Like Peptide-1 Receptor
0
Glycated Hemoglobin A
0
Hypoglycemic Agents
0
efpeglenatide
3M1V5Z2270
Liraglutide
839I73S42A
Metformin
9100L32L2N
Proline
9DLQ4CIU6V
Banques de données
ClinicalTrials.gov
['NCT02057172']
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1733-1741Informations de copyright
© 2019 by the American Diabetes Association.